Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer

Summary

This is a Multicenter, Non-randomized, Open Label, Multiple Dose, Multiple administration, Phase IIa Clinical Study Evaluating the Efficacy and Safety of LY01610 in Patients with Extensive-stage Small Cell Lung Cancer that Progressed after first-line Antitumor Therapy.

Timeline

Start

2020-09-28

Primary completion

2023-03-04

Completion

2023-03-04

Drugs

Indications